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1 Introduction
Due to the worldwide epidemic of severe 
acute respiratory syndrome (SARS) from 2002 to 
the winter of 2003 and the emergence of avian 
influenza in 2004 in and around Asia, infectious 
disease measures are now an urgent issue. “Policy 
for the allocation of budget and human resources 
to science and technology for 2004 (Council for 
Science and Technology Policy, June 19, 2003)” 
states that “measures against emerging infectious 
diseases and bioterrorism are new and important 
considerat ions that must be researched.” 
“Infectious disease research” and “biodefense 
research” are both recognized as important 
issues in the United States. The budget message 
for fiscal 2005 announced on February 2, 2004 
designated infectious diseases as priority areas 
to be dealt with in National Institutes of Health 
(NIH)[1,2]. 
By  the  1970 s ,  adva nces  i n  d i ag nos t ic ,  
prophylactic and therapeutic agents encouraged 
people to believe that infectious diseases are 
conquerable threats. However, the emergence 
of  un k nown i n fec t ious d i seases  and the 
re -emergence of infectious diseases that were 
considered conquered, as well as the need for 
anti-bioterrorism measures, have heightened the 
urgency of infectious disease research.
This report provides general information on 
infectious diseases and discusses the importance 
of basic research on infection and disease 
development mechanisms that will serve as the 
basis for developing prevention and treatment 
methods.
2 Infectious diseases
Infectious diseases are result from infection by 
pathogens. Symptoms develop due to interaction 
between the pathogen and the infected host. 
Pathogens can be parasites, fungi, viruses, 
bacteria or prions, which are all parasitic agents 
that are further classified by size, the presence 
or absence of genomes, and self -propagation 
ability (Table 1). Organisms with nuclei such as 
parasites and fungi are called eukaryotes, while 
those without nuclei such as bacteria are called 
prokaryotes.
Microorganisms Size Propagation as parasites Genome Self-propagation
Prion — Capable Absent Incapable
Virus 0.02 ~ 0.3µm Capable Present Incapable
Bacteria 0.1 ~ 5µm Capable Present Capable
Fungi ~ 50µm Capable Present Capable
Parasite — Capable Present Capable
Source: Prepared by Professor Akio Nomoto of the Graduate School of Medicine, the University of Tokyo.
Table 1 : Classification of pathogens
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2-1 Parasitic infections
Parasites are medically defined as parasitic 
eukaryotes other than fungi and can be further 
classified into unicellular protozoans, such as 
malaria and trypanosoma, and multicellular 
helminth represented by filaria. Diseases caused 
by parasites are called parasitic infections.
The Special Programme for Research and 
Training in Tropical Diseases (TDR) of the World 
Health Organization (WHO) have designated 
ma la r i a ,  t r ypanosomias i s ,  le i shman ias i s ,  
filariasis, schistosomiasis and leprosy as the 
six hard-to -conquer diseases, all of which are 
parasitic infections except leprosy.
In Japan, the number of intestinal parasites has 
decreased with improved water and sewerage 
systems, but the Japanese habit of eating raw 
fish is still causing a high anisakiasis infection 
rate. Moreover, cryptosporidiosis caused by 
contaminated tap water broke out in 1994 and 
1996 in Kanagawa and Saitama Prefectures, 
respectively[3].
2-2 Bacterial infections
Bacteria are prokaryotes that can make copies 
of themselves through self-replication wherever 
nutrients are available. Based on their activities 
and their influence on human beings, bacteria 
are classified into three groups, i.e., harmless, 
harmful, and effective bacteria, which co-exist in 
the human intestine. Effective bacteria produce 
lactic acid by breaking down proteins, while 
harmful bacteria produce ammonia, amines 
or indoles through putrefaction. In bacterial 
infection, the toxins produced by the bacteria 
trigger disease development[4].
Typical examples of bacter ia l in fections 
are enterohemorrhagic E. coli (strain O157) 
infections, pertussis and dysentery. Antibiotics 
are effective against bacterial infections, but 
their overuse has resulted in the emergence of 
drug-resistant bacteria such as drug-resistant 
tuberculosis, methicillin-resistant staphylococcus 
aureus (MRSA) and vancomycin - res i s tant 
enterococcus (VRE). VRE is an especially difficult 
disease because most antibiotics currently used 
for treatment of infection prove ineffective in 
most cases.
2-3 Viral infections
Viruses have a simple structure consisting 
of a genome for replicating itself and proteins 
and lipids for protecting the genome. It cannot 
replicate by itself due to the absence of functions 
such as nutrient consumption, energy production 
and protein synthesis, and must therefore live on 
other cells to utilize their functions and replicate.
The first step in viral infection is the infection 
and propagation of the virus at the site of damage 
to a mucous membrane or the skin. Whether it 
infects the respiratory mucosa or the digestive 
mucosa depends on the kind of virus. Some 
viruses replicate and symptoms develop in the 
first target cell, while others enter the capillaries 
to travel through the body in the bloodstream to 
reach the final target tissue where they replicate 
and the disease develops[5,6].
Vaccines utilizing the immune function of 
the host have been used for preventing viral 
infections. As a result, worldwide eradication 
of smallpox was achieved in 1979. Eradication 
of poliomyelitis is also in progress under the 
leadership of WHO.
Among the considerable number of viral 
i n fect ions known today,  SA RS caused by 
coronavirus infection and influenza caused by 
influenza virus infection are perhaps attracting 
most public attention. In addition, koi herpesvirus 
infection found in carp cultured in Kasumigaura 
has become a serious problem because of its 
economic consequences, while avian influenza 
has become a great concern due to both its 
economic influence and the possibility that it will 
infect humans.
2-4 Prion diseases
Prion diseases such as sheep scrapie were 
considered to be special forms of viral diseases 
with a long incubation period following viral 
infection. However, in the 1980s, it was proposed 
that these diseases are caused by abnormal prion 
proteins, and this has been confirmed through an 
experiment demonstrating that abnormal prion 
proteins are capable of inducing neuronal disease. 
Prion disease is a general term for diseases 
thought to be caused by abnormal prion proteins. 
To date, l ittle is known about the infection 
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mechanism or the action of prion proteins[7].
Examples of prion diseases are sheep scrapie, 
bovine spongiform encephalopathy (BSE) and 
human Creutzfeldt-Jakob disease (CJD).
3 Major problems concerning
 infectious diseases
Infectious diseases, the most common cause 
of human fatalities, have always been and will 
remain a problem that must be overcome. 
Awareness of infectious diseases is growing. 
The following are some major issues concerning 
infectious diseases.
3-1 Emerging and re-emerging
 infectious diseases
WHO defines emerging infectious diseases as 
“those due to newly identified and previously 
unknown infections that cause public health 
problems either locally or internationally,” and 
re -emerging infectious diseases as “those due 
to reappearance and increase of infections that 
are known, but had formerly fallen to levels so 
low that they were no longer considered a public 
health problem”[6,8]. Examples of emerging and 
re-emerging infectious diseases are listed in Table 
2.
It is unlikely that emerging infectious diseases 
are caused by completely new viruses; rather, 
they are considered to be caused by zoonotic 
viruses (those infecting humans as well as other 
animals). Such viruses remained undiscovered, 
coexisting with their natural hosts away from 
human beings, but once they encounter human 
communities, they start emerging as ‘new’ 
diseases.
3-2 Imported infectious diseases
Aircraft and other transportation means have 
increased the circulation of supplies as well 
as people. This has also increased the risk of 
importing infectious diseases from other areas.
In 1967, an infection with a fatality rate of 
23% attacked workers in Behring Laboratory in 
Marburg. This disease, named Marburg disease, 
was caused by a virus carried by an African green 
monkey shipped from Uganda. Ugandan monkeys 
were also exported to Japan around the same 
time, although they were uninfected by the virus.
In 1976, an Amer ican woman return ing 
from Sierra Leone was found to be infected 
by the Lassa virus, and 552 people who had 
potentially had contact with her were placed 
under surveillance for 3 weeks. Fortunately, no 
secondary infection was observed in this case.
In 1987, a Japanese technician also returning 
from Sierra Leone was diagnosed as having Lassa 
fever after receiving medical treatment at the 
Research Hospital of the Institute of Medical 
Science, The University of Tokyo.
Table 2 : Examples of emerging and re-emerging infectious diseases
Emerging infectious diseases Re-emerging infectious diseases
Parasitic infections Cryptosporidiosis
Malaria
Leishmaniasis
Echinococcosis
Bacterial infections
Enterohemorrhagic E. coli (strain O157) 
infections
Novel strain of cholera (Bengal cholera)
Legionellosis
Fulminant type-A streptococcus 
infections
Plague
Diphtheria
Tuberculosis
Pertussis
Salmonellosis
Cholera
Viral infections
Ebola hemorrhagic fever
Hantavirus pulmonary syndrome
HIV (AIDS)
Adult T-cell leukemia
Nipah virus encephalitis
SARS
Rabies
Dengue/ dengue hemorrhagic fever
Yellow fever
Source: Prepared by the author based on the Reference [3].
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3-3 Drug-resistant bacteria
Since the discovery of penici l l in and its 
first clinical application in 1941, many kinds 
of antibiotic have been put into practical use. 
Antibiotics are effective against infectious 
diseases, especially against bacterial infections, 
and have contributed to the dramatic reduction 
in many acute infections, at least in developed 
countries. Antibiotics have also been effective 
against certain chronic infections, such as 
tuberculosis, which has drastically reduced the 
number of tuberculosis patients. However, while 
exerting such dramatic effect against bacterial 
infections, antibiotics have generated the new 
problem of the emergence of drug - resistant 
bacteria.
3-4 Bioterrorism
Japan’s Aum Shinrikyo’s dispersal of anthrax 
and botulinum as well as sarin in a sarin gas 
attack and U.S. anthrax mail threats in 2001[7] 
have impressed the reality of bioterrorism on the 
international community.
This has raised the demand for anti-bioterrorism 
measures, especially in the United States, where 
the budget for anti -bioterrorism measures has 
been increased[2] over the past few years.
4 Importance of understanding
 the molecular mechanisms
 of infection and development
Various factors are involved in the emergence 
of drug - resistant bacteria and emerging or 
re -emerging infectious diseases. For example, 
delay in public health improvement due to 
poverty or jungle exploitation that accompanies 
rapid population expansion has increased the 
risk of encountering unknown pathogens, and 
abnormal weather patterns consistent with 
global warming have increased or altered the 
distribution of the natural hosts of pathogens. 
Furthermore, inadequate or excessive use of 
antibiotics and the aging of society have lead 
to the emergence of symptoms that cannot 
be controlled by the immune system. These 
problems cannot be easily solved, yet they are 
likely to grow into even more serious problems. 
Therefore, we must work harder to strengthen 
measures against infectious diseases.
To establish new prevention and treatment 
methods other than existing vaccine-mediated 
prevention and symptomatic treatment, it 
is impor tant to understand the molecular 
m e c h a n i s m s  o f  i n f e c t i o n  a n d  d i s e a s e  
development and to utilize the results to develop 
new prevention and treatment methods.
4-1 Importance of understanding
 the molecular mechanisms of infection
 and development
Developing new prevention and treatment 
methods requires elucidation of the molecular 
mechanisms of the infection process and the 
disease development process.
For example, focusing on the fact that viruses 
cannot propagate without using the molecules 
or systems of their hosts, research projects 
are in progress to identify the host - derived 
molecules determining the species -, tissue- or 
cell-specificity of viruses to reveal the biological 
processes by which viruses adhere to or invade 
cells, replication of the viral genome, virus 
particle formation and cell death. Unfortunately, 
the molecular mechanisms of infection and 
disease development have only been partially 
elucidated, even for substantially eradicated 
viruses such as poliovirus.
Research on bacterial infections has been 
promoted  to  u nde r s t a nd  t he  molec u l a r  
mechanisms underlying the processes of bacterial 
fixation and invasion into tissues or cells at 
infection sites, and inflammation resulting from 
bacterial phagocytosis due to the release of 
macrophages and cytokines. However, these 
mechanisms are not yet fully understood.
4-2 Process of virus infection research
The following example of virus infection 
research illustrates the process for elucidating 
infection and disease development mechanisms.
The first step of invasion into a host organism 
is the propagation of the virus at the first target 
cell. The disease then develops at this site, or 
travels through the host to other tissues where 
they propagate and where the disease develops. 
However, if the host lacks the receptor that binds 
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to the virus, infection does not occur.
Pathogen icit y studies of v i ruses a im to 
e luc idate  “ the  mecha n i sm of  spec ies  or  
t issue - speci f icity determination,” “in vivo 
transmission mechanism” and “the capacity to 
damage the final target cell.” Viral propagation 
depends on the compatibi l ity of molecules 
between the virus and the host. The mechanism 
and route of the in vivo transmission of viruses 
to the final target cell are the important steps in 
disease development.
For example, poliovirus shows species-specificity 
that  l im it s  i t s  i n fect ion to pr imates  and 
tissue-specificity that limits its site of propagation 
to the central nervous system and the intestines. 
After in vivo transmission, polioviruses release 
their toxins in the final target, the nerve cells. 
They use a cel l - surface receptor molecule 
(poliovirus receptor) for infection that has 
been cloned and that is suggested to be the 
determinant for species-specificity. In addition, 
the appl icat ion of genet ic transformation 
technology has revealed the genomic sequence 
of viruses with tissue-specificity (central nervous 
system-specificity). The mechanism of the in 
vivo transmission of the virus is being currently 
studied using an infection model established with 
mice[5].
The elucidation of the molecular mechanism of 
viral infection and disease development is very 
important, as it serves as a basis for developing 
infectious disease measures such as prevention 
and treatment methods. Findings on the process 
of viral invasion into the host can be applied to 
developing measures to be taken at the initial 
stages of infection, while findings on in vivo 
transmission and viral replication in target cells 
can be used to suppress disease development 
(Figure 1).
5 Suggestions
 — Infectious disease research
      for public safety 
  and peace of mind —
As mentioned in Section 3, there are many 
problems concerning infectious diseases, and it is 
essential to promote infectious disease research 
to establish a safe society with peace of mind in 
Japan. Here are some suggestions for strategies to 
be taken.
5-1 Fostering and securing human resources
 and research funds
Emerging infectious diseases are likely to 
be caused by pathogens belonging to known 
taxonomic groups in the pathogen classification. 
Therefore, basic knowledge of major known 
pathogens should prove useful in taking effective 
measures against novel pathogens. For example, 
Figure 1 : Process for elucidating viral infection and disease development mechanisms
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measures against SARS caused by a newly 
discovered coronavirus were developed based on 
knowledge and techniques already established for 
other coronaviruses.
Therefore, it is important to establish a system 
for supporting basic research on major pathogens. 
While further research should be conducted for 
pathogens that have already been researched, 
research on non - researched pathogens must 
also be enhanced to encourage this entire area 
of research. Such projects must be promoted to 
prepare for the future emergence of emerging 
and re-emerging infectious diseases.
To promote research on molecular mechanisms, 
the routine gathering of fundamental knowledge 
and establishing of experimental methods and 
techniques, it is essential to foster and secure 
human resources and research funds in this 
area. However, compared to the United States, 
Japan has allocated an extremely small amount 
of human resources and research funds to the 
infectious disease research area (Table 3).
Consider ing the signi f icant inf luence on 
public health and the unpredictable nature of 
their epidemics, infectious diseases are an issue 
that must be continuously tackled. Fundamental 
knowledge on molecular mechanisms and 
experimental methods cannot be established 
without accumulating research results, and 
specialists handling peculiar pathogens cannot 
be raised in a short time. Reduced emphasis on 
infectious disease research may result in reduced 
research support and ultimately in the outflow of 
researchers to other research areas. This must not 
happen.
5-2 Enhancement of Biosafety Level 4
 facilities considering linkage
 with other countries 
E xper i ment s  u s i ng  i n fec t iou s  d i s ea se  
pathogens require special research facilities 
(hardware) and appropriate action (software) by 
workers to prevent infection and environmental 
contamination.
S t a n d a r d s  f o r  h a n d l i n g  p a t h o g e n i c  
microorganisms have been establ ished by 
WHO and set out in the Laboratory Biosafety 
Manual. In the United States, standards have 
been jointly established by NIH, the largest 
domestic institution in U.S. responsible for 
biomedical research, and Centers for Disease 
Control and Prevention (CDC), an international 
organization playing a central role in infectious 
disease measures. In Japan, the National Institute 
of Infectious Diseases has established safety 
management principles, while the Bioscience 
Sector in the Subdivision on the Focused 
Promotion of Basic and Fundamental Research 
and Development, Counci l for Science and 
Technology, has established “Manual for the 
Safe Management of Research Microorganisms 
in University Laboratories, etc.” in January 1998. 
Various academic societies have also established 
their own guidelines (Table 4).
“B iohaza rd ,”  the  abbrev i a ted  te r m for  
“biological hazard,” refers to a hazard caused 
Human resources
U.S Centers for Disease Control and Prevention (CDC) About 3,400 people*
Japan National Institute of Infectious Diseases About 400 people
R&D expenditures
U.S Centers for Disease Control and Prevention (CDC) About 57 billion yen**
Japan National Institute of Infectious Diseases About 3.3 billion yen***
*   The value was predicted based on the assumption that the proportion of personnel engaged in infectious 
disease research, which was assumed to have been about 40% in 1997 based on reference material in 1997, 
has not changed since then.
**  This also includes the expenditures for chronic diseases, etc., other than infectious diseases
***   The value obtained as the sum of the 2002 annual research budget allocated for the institute (about 1.8 billion 
yen) and competitive funds such as research grants from the Ministry of Health, Labor and Welfare (about 1.5 
billion yen)
Table 3 : An example of allocation of human resources and funds to infectious disease research
Source:  Prepared by the author based on the reference material distributed in the 34th Council for Science and 
Technology Policy.
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by organisms (microorganisms) harmful to 
humans or the environment. The fundamental 
rule in biohazard measures is the containment 
of pathogens, and action taken for this purpose 
consists of two steps, i.e., primary isolation and 
secondary isolation. The former is to protect 
workers from exposure to pathogens, while 
the latter is to isolate the laboratory from the 
outside environment. These actions are assigned 
Biosafety Levels (BSL) 1- 4[9] according to the 
degree of hazard.
In Japan, the National Institute of Infectious 
Diseases and the Institute of Physical and 
Chemical Research (RIKEN) each has a laboratory 
that satisfies the conditions required for BSL4 
facilities. In both laboratories, maintenance such 
as the replacement of filters and other equipment 
as well as occasional inspections are conducted, 
but to date, neither is planned to be used as a 
BSL4 laboratory.
Pathogens potentia l ly causing impor ted 
infectious diseases include those that can only 
be handled in BSL4 laboratories, such as the 
Ebola virus and Marburg virus. Furthermore, 
BSL4 laboratories may be needed for handling 
unidentified pathogens. The lack of operational 
BSL4 laborator ies is retarding progress in 
domes t ic  re sea rch  on  h ig h ly  ha za rdous  
pathogens.
To promote  such resea rch projec t s ,  i t  
is important to establ ish operational BSL4 
laboratories where high safety levels are ensured. 
Linkage with overseas facilities should also be 
considered to create a research environment 
equipped with available BSL4 laboratories.
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